Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03093428
Title Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02115 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field